Bayer (BAY) and Onyx Pharmaceuticals (ONXX) are opening a randomized, double-blind Phase III trial in which sorafenib will be administered with chemotherapies carboplatin and paclitaxel to patients with advanced metastatic melanoma.
The companies expect the trial to enroll more than 200 patients. The primary endpoint is progression-free survival. Patients will be randomized to receive 400 mg of oral sorafenib twice daily or a matching placebo, in addition to a standard dosing schedule of carboplatin and paclitaxel. The study will include sites in the U.S., Canada, Europe and Australia. Sorafenib is being evaluated both as a single therapy agent and in combination with other oncology agents in a number of clinical trials. Shares of Onyx were down 73 cents, or 2.3%, to $31.71, and Bayer's American depositary shares were losing 40 cents, or 1.2%, to $33.04.>To order reprints of this article, click here: ReprintsTheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,801.23 | 1,342.64 | 2,903.88 | 19.69 |
Oil *
117.67
|
|
DOWN
89.23 |
DOWN
9.31 |
DOWN
23.35 |
DOWN
0.78 |
10 Yr
1.97%
SPDR Gold
167.14
|
|
-0.69%
|
-0.69%
|
-0.80%
|
-3.81%
|
Data delayed 20 minutes |
Connect with TheStreet